Kidney HealthMar 15, 2026
Sodium polystyrene sulfonate, commonly sold as Kayexalate, has been prescribed for decades to bring down high potassium levels, especially in people with kidney disease. Yet the evidence supporting it is surprisingly thin, and the potential harms are anything but trivial. In a systematic review of gastrointestinal injury cases, roughly one in three patients with serious bowel damage from this drug died. That is not a footnote. It is the central tension of a medication still widely used in hospitals and clinics today.
The core problem is a mismatch between expectation and reality. Patients and even some clinicians treat SPS as though it is a reliable, fast-acting fix for dangerous potassium levels. The research tells a different story: modest potassium reductions, an onset measured in hours to days, and a risk profile that includes bowel necrosis, heart failure, and interference with other medications you may be taking at the same time.
DiabetesMar 15, 2026
A single patch the size of a postage stamp delivered semaglutide for an entire month in animal studies, mimicking four weekly injections from one 2×2 cm application. That is genuinely exciting. It is also, for now, entirely experimental. No GLP-1 patch is approved or commercially available for diabetes or obesity. Every current GLP-1 receptor agonist, including semaglutide, liraglutide, dulaglutide, and tirzepatide, reaches patients through injections or, in the case of oral semaglutide, a daily pill.
So if you have seen headlines about GLP-1 patches and wondered whether you should ask your doctor about one, the honest answer is: not yet. But the research pipeline is worth understanding, because it signals where treatment is headed.
Respiratory HealthMar 15, 2026
For years, a real concern hung over this drug: could adding a long-acting bronchodilator to an inhaled steroid increase the risk of serious asthma events? Large randomized controlled trials in adolescents and adults have now answered that clearly. Fluticasone salmeterol does not raise the risk of asthma-related deaths, intubations, or hospitalizations compared to fluticasone alone. What it does is reduce severe exacerbations by roughly 20 to 21%.
In COPD, the picture is more complicated. The symptom benefits hold up, but fluticasone salmeterol consistently increases pneumonia risk. Same drug, meaningfully different risk profiles depending on the disease being treated.
Hair HealthMar 15, 2026
Multiple meta-analyses now converge on a clear conclusion: combining finasteride and minoxidil produces better hair regrowth than using either one by itself. A 2025 network meta-analysis that ranked minoxidil-based regimens for men placed the finasteride-plus-minoxidil combination at the top. And a separate 2025 meta-analysis of seven randomized controlled trials found that topical finasteride-minoxidil formulations improved hair density by roughly 9 hairs per square centimeter over minoxidil alone, along with gains in hair diameter and overall global assessment scores.
The more practical question isn't whether the combination works better. It does. The real question is which version of the combination makes sense for your situation: oral pills, topical liquids, or some mix of both.
Cardiovascular HealthMar 15, 2026
Sodium thiosulfate has been saving lives in emergency rooms since 1912, and it still sits on the WHO's list of essential medicines. But the most interesting story isn't the one everyone already knows. Researchers are now finding that this simple sulfur compound does far more than neutralize poisons: it scavenges damaging free radicals, protects mitochondria, tames inflammation, and behaves like a signaling molecule tied to hydrogen sulfide, one of the body's own gaseous messengers.
The catch? Most of those newer roles have only been demonstrated in animal models and lab studies. What sodium thiosulfate (STS) can reliably do in humans right now, and what it might do in the future, are two very different conversations. Both are worth having.
AntibioticsMar 15, 2026
The largest modern randomized trial on this topic found that methenamine hippurate, taken twice daily, was non-inferior to daily low-dose antibiotics for preventing recurrent UTIs over 12 months. The gap between them was real but small enough to fall within the study's predefined "close enough" threshold. The critical difference: methenamine hippurate has no known tendency to promote antimicrobial resistance, while months or years of prophylactic antibiotics certainly can.
Methenamine hippurate has been around for decades, but it's attracting renewed attention as antibiotic stewardship climbs the priority list. Clinical guidelines are starting to acknowledge the newer trial evidence, and for women stuck in the cycle of repeated infections and repeated prescriptions, it represents a genuinely different approach.
Cholesterol ManagementMar 15, 2026
Most people think of HDL as the "good cholesterol" and assume more is better. But the protein that makes HDL work, apolipoprotein A1 (ApoA1), tells a more complicated story. Research shows that both very low and very high levels of ApoA1 are linked to increased mortality, creating a U-shaped risk curve that challenges the simple "higher is healthier" assumption. Even more striking: ApoA1 can become oxidized inside arterial plaques, flipping from a protective molecule into one that actively promotes inflammation.
This shift in understanding, from how much ApoA1 you have to how well it actually functions, is reshaping how researchers think about cardiovascular risk and treatment.
Irritable Bowel SyndromeMar 15, 2026
Most drugs for irritable bowel syndrome with constipation (IBS-C) get absorbed into your bloodstream and work from the inside out. Ibsrela (tenapanor) takes the opposite approach. It acts almost entirely within the gut itself, with very low absorption into the body. That local-only design is central to both how it works and why its safety profile looks the way it does.
FDA-approved in 2019, Ibsrela at 50 mg twice daily improved both constipation and abdominal pain in trials involving more than 1,200 adults. The trade-off is straightforward: diarrhea is the most common side effect, but it tends to be mild to moderate and shows up early rather than building over time.
Sleep ApneaMar 15, 2026
Oral appliances reduce apnea severity less than CPAP on paper, yet they produce similar long-term treatment success in many people with mild to moderate obstructive sleep apnea. That counterintuitive finding captures something important about how OSA treatment actually works in real life: the best therapy is often the one you'll actually use, not the one with the most impressive numbers in a lab.
CPAP remains the gold standard for lowering the apnea-hypopnea index (AHI, the number of breathing disruptions per hour) and improving blood oxygen levels, particularly in severe OSA. But "gold standard" doesn't mean "only standard." A growing body of research supports several alternatives, each with distinct strengths, limitations, and ideal candidates.
AnxietyMar 15, 2026
Gabapentin prescriptions for anxiety are climbing, but there's a disconnect between how often it's prescribed and what the evidence actually supports. For generalized anxiety disorder, the condition most people think of when they hear "anxiety," there are zero randomized controlled trials. Not weak trials. Zero. The evidence that does exist is limited to case reports and small uncontrolled observations. Where gabapentin shows real promise is in narrower, more specific situations: social anxiety, pre-surgical nerves, and anxiety related to breast cancer treatment.
That gap between widespread use and thin evidence matters if you're considering this medication or already taking it. SSRIs, SNRIs, and cognitive behavioral therapy remain the standard first-line treatments for anxiety disorders, and gabapentin sits firmly in the off-label, second- or third-line category.
AntibioticsMar 15, 2026
Fidaxomicin and vancomycin clear a C. difficile infection at roughly the same rate. Where fidaxomicin pulls ahead, and it's not subtle, is in what happens next: significantly fewer people relapse. If you've dealt with C. diff before, or if you're facing treatment decisions right now, that distinction between "cured" and "cured and staying that way" is the whole ballgame.
Fidaxomicin is a narrow-spectrum macrolide antibiotic taken by mouth. It barely gets absorbed into the bloodstream, which means it concentrates where C. diff actually lives: your gut. And because it's narrow-spectrum, it does far less collateral damage to your normal gut bacteria than older treatments. That preservation of your microbiome appears to be a big part of why recurrence rates drop.
Sleep ApneaMar 15, 2026
Inspire, the implanted device for obstructive sleep apnea, reduces the number of breathing disruptions per hour by roughly 50 to 57 percent, and people actually use it. Real-world data shows patients keep it on about 5.5 to 6 hours a night, on approximately 90 percent of nights. That adherence figure alone sets it apart from CPAP, the treatment most people with moderate-to-severe OSA are told to use first and many abandon.
But Inspire is not a universal fix. It works well for a carefully selected slice of the OSA population, and the selection criteria are strict for good reason. Here is what the research actually supports, who stands to benefit, and where the limits are.
Cardiovascular HealthMar 15, 2026
Repatha (evolocumab) drops LDL cholesterol by roughly 50 to 60 percent on top of whatever therapy you're already on. That's a striking number, especially for people who've already maxed out on statins and lifestyle changes. It also translates into a 15 to 20 percent relative reduction in major cardiovascular events like heart attacks and strokes.
But this isn't a first-line treatment you'd pick up at the pharmacy alongside a multivitamin. Repatha is a subcutaneous injection reserved for specific high-risk groups: people with established cardiovascular disease, familial hypercholesterolemia, or those who genuinely can't tolerate statins. Understanding where it fits, and where it doesn't, matters.
Prostate CancerMar 13, 2026
Eligard, an injectable form of leuprolide acetate, pushes testosterone down to castrate levels in the vast majority of men with prostate cancer. But "vast majority" ranges from 94% to 98% with shorter dosing intervals, dropping to roughly 88–90% with the longest option. That gap is worth understanding if you or someone you care about is choosing between a shot every month versus every six months.
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
Cardiovascular HealthMar 13, 2026
Catheter ablation is the most effective long-term treatment for atrial tachycardia, yet medications, the usual first step most people encounter, have only moderate long-term efficacy. That gap between what works best and what you're likely to be offered first is worth understanding if you or someone close to you has been diagnosed with this rhythm disorder.
Atrial tachycardia (AT) is a type of supraventricular tachycardia (SVT), meaning the abnormally fast heartbeat originates above the ventricles, specifically in the atria (the upper chambers of the heart). Unlike some other SVTs, AT fires independently of the AV node (the electrical relay station between your upper and lower chambers). It is less common than other SVTs, but it is clinically important because, if it becomes incessant, it can lead to cardiomyopathy or heart failure.
MedicationsMar 13, 2026
Dorzolamide has been a reliable workhorse for lowering eye pressure in glaucoma for years. But the more interesting story right now is what researchers are finding it can do beyond the eye: fighting antibiotic-resistant bacteria and taming inflammation through modified versions of its chemical structure. It is still primarily a glaucoma drug, and a good one, but its second life in the lab suggests this molecule has chapters left to write.
For the millions of people actually using dorzolamide today, though, the practical questions are simpler. How well does it work? What does it feel like? And when is it the right choice over other options?
